Fulvestrant Deemed Effective as Later-Line Breast Cancer Treatment

In In The News by Barbara Jacoby

Spread the love

Source: Conference Coverage

From: cancertherapyadvisor.com

Advertisment

Fulvestrant was found to be effective as an early and later-line treatment for women with hormone refractory metastatic breast cancer, according to the results of a retrospective study reported at the 17th St. Gallen International Breast Cancer Conference 2021.

To conduct the study, researchers reviewed the medical records of women with hormone receptor-positive metastatic breast cancer who began treatment with fulvestrant in Saskatchewan, a Canadian province, via an access program between 2003 and 2019.

Multivariate analysis identified having no visceral metastasis as correlating with improved time to progression (HR=0.701; P =.046) but not OS (HR=1.783;  P=.261). Also, having received fewer than 2 prior lines of therapy before starting treatment with fulvestrant was associated with improved OS (HR=0.139; P =.001).

“Fulvestrant has demonstrated efficacy as both early and later line therapy in metastatic breast cancer,” the study researchers concluded.

Visit Cancer Therapy Advisor’s conference section for more coverage of the 17th St. Gallen International Breast Cancer Symposium.

Reference

Andrahennadi S, Sami A, Haider K, et al. Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience. Presented at: The 17th St. Gallen International Breast Cancer Conference 2021; March 17-21, 2021. Abstract P056.

A total of 186 women were identified for study and grouped into 2 cohorts: those who received 2 or fewer prior lines of therapy before starting treatment with fulvestrant (102 women) and those who received 3 or more prior lines (84 women).

The median time to progression was 12 months for women who received 2 or fewer prior lines of therapy and 6 months for women who received 3 or more prior lines (P =.015). The median overall survival (OS) was 26 months for women who received 2 or fewer prior lines of therapy and 16 months for women who received 3 or more prior lines (P =.067).